Clinical trials: Glaucoma Therapy
Open-angle Glaucoma, Ocular Hypertension
Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV®
The purpose of this study is to evaluate the additive intraocular pressure (IOP) lowering effect of Brinzolamide 1%/Brimonidine 0.2% (SIMBRINZA®) dosed twice daily (BID) when added to Travoprost 0.004%/Timolol 0.5% (DUOTRAV®) in…
- Trial name
- NCT02730871
- Testing
- Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, Brinzolamide/brimonidine vehicle, Travoprost 0.004%/timolol 0.5% solution
- Where
- United States
- Volunteers
- 173 people
- Sponsor
- Alcon Research
Open-Angle Glaucoma, Ocular Hypertension
A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension
The purpose of the study is to evaluate the safety and effectiveness of an investigational glaucoma therapy in patients with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT00293800
- Testing
- Travoprost 0.004%/Timolol 0.5% Ophthalmic Solution, Latanoprost 0.005% Ophthalmic Solution (XALATAN), Timolol 0.5% Ophthalmic Solution
- Volunteers
- 173 people
- Sponsor
- Alcon Research
Open-angle Glaucoma, OAG
A Study to Evaluate Adverse Events and Change in Disease Activity With the XEN45 Glaucoma Treatment System Implantation In Adult Participants With Open-Angle Glaucoma in China
Glaucoma is the second most common cause of blindness in the world, second only to cataracts. The purpose of this study is to assess adverse events (AEs) and changes in disease activity in participants with open-angle glaucoma…
- Trial name
- NCT05821855
- Testing
- XEN45 Glaucoma Treatment System, Trabeculectomy
- Where
- 13 sites in China
- Volunteers
- 120 people
- Sponsor
- AbbVie
Open Angle Glaucoma or Ocular Hypertension
OPC-1085EL in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Chinese Subjects
It is a phase III, multi-center, randomized, single-blind (to evaluator), parallel, and positive-controlled clinical trial evaluating the efficacy and safety of OPC-1085EL in the treatment of primary open angle glaucoma or ocular…
- Trial name
- NCT05583474
- Testing
- OPC-1085EL, 0.005% Latanoprost
- Where
- China
- Volunteers
- 204 people
- Sponsor
- Otsuka Beijing Research Institute
Glaucoma
Satisfaction With XEN Gel Stent Versus Trabeculectomy for the Treatment of Glaucoma
This is a prospective, observational, non-interventional study of patients scheduled to receive surgical intervention either via XEN or trabeculectomy for open-angle glaucoma.
- Trial name
- XENPRO (NCT03852810)
- Where
- 10 sites in Canada, Germany and 1 more
- Volunteers
- 28 people
- Sponsor
- Allergan
Primary Open-Angle Glaucoma, Optic Nerve Injury
A Phase II Trial of G01 Eye Drops for Glaucomatous Optic Neuropathy
This is a randomized, double-masked, placebo-controlled Phase II clinical trial. The primary objective is to explore the efficacy of G01 Eye Drops in the treatment of optic nerve injury associated with open-angle glaucoma…
- Trial name
- NCT07777861
- Testing
- G01 Eye Drops 100μg/ml, G01 Eye Drops 200μg/ml
- Where
- 9 sites in China
- Volunteers
- 90 people
- Sponsor
- Qingdao WanMing BioCell Pharmaceutics Co.,Ltd.
Glaucoma, Ocular Hypertension
Safety and Efficacy of Adding AZARGA® Adjunctive to Prostaglandin Therapy
The purpose of this study was to evaluate the safety and efficacy of adding AZARGA® as a single agent to prostaglandin monotherapy in patients with either ocular hypertension or primary open-angle glaucoma.
- Trial name
- NCT01263444
- Testing
- Brinzolamide 1% / timolol 0.5% Fixed Combination, Habitual prostaglandin monotherapy
- Volunteers
- 47 people
- Sponsor
- Alcon Research
Open Angle Glaucoma
Surgical Treatment of Refractory Open Angle Glaucoma
The primary objective of this study is to evaluate the safety, efficacy, and performance of the Suprachoroidal Dissection Instrument in creating a fistula between Schlemm's canal and the suprachoroidal space in refractory, open…
- Trial name
- NCT01212861
- Testing
- Suprachoroidal Dissection Instrument (SDI)
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- iScience Interventional Corporation
Glaucoma, Primary Open Angle (POAG), Ocular Hypertension
Determination Of Predictive Factors Allowing To An Additional 10% Reduction Of Intra-Ocular Pressure
To determine the predictive factors of a positive response to latanoprost 0.005% / timolol 0.5% fixed combination (defined as a 10% IOP reduction from baseline), after 12 weeks of treatment (age, sex, ethnic origin, patient's…
- Trial name
- PREDICOM (NCT00230763)
- Testing
- GSS questionnaire, IOP, LATANOPROST 0.005% / TIMOLOL 0.5% FIXED COMBINATION
- Where
- 102 sites in France
- Volunteers
- 396 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Open-angle Glaucoma, Ocular Hypertension
A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension
The purpose of this study is to determine whether a glaucoma therapy is safe and effective in treating patients with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT00287521
- Testing
- AL-37807 Ophthalmic Suspension, 1.0%, Latanoprost, 0.005% (Xalatan), AL-37807 Vehicle
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- Alcon Research
Primary Open Angle Glaucoma of Both Eyes
Comparative Study of Dorzotimol Eye Drops, 20 mg/mL + 5 mg/mL Versus Cosopt® Eye Drops, 20 mg/mL + 5 mg/mL
The goal of this study is to compare efficacy and safety of Dorzotimol eye drops, 20 mg/mL + 5 mg/mL manufactured by JADRAN-GALENSKI LABORATORIJ d.d.
- Trial name
- NCT05973318
- Testing
- Dorzotimol eye drops, 20 mg/mL + 5 mg/mL, Cosopt eye drops, 20 mg/mL + 5 mg/mL
- Where
- Russia
- Volunteers
- 110 people
- Sponsor
- Jadran Galenski laboratorij d.d.
Glaucoma, Open-angle
Non Interventional Study With Primary Open Angle Glaucoma and/or Ocular Hypertension Patients Treated With Xalacom® After Failure of Previous Antiglaucoma Therapy.
This study is designed to evaluate the safety and tolerability of Xalacom in patients with primary glaucoma
- Trial name
- NCT00801437
- Testing
- Xalacom
- Where
- 39 sites in Slovakia
- Volunteers
- 457 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Retinal Disease, Macular Degeneration
Stem Cell Ophthalmology Treatment Study
This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease. http://mdstemcells.com/scots-ii/
- Conditions
- Retinal Disease, Macular Degeneration, Hereditary Retinal Dystrophy, Optic Nerve Disease
- Trial name
- SCOTS (NCT01920867)
- Testing
- RB (Retrobulbar), ST (Subtenon), IV (Intravenous)
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- MD Stem Cells
Medication Adherence, Glaucoma
A Universal Eye Drop Adherence Monitor to Measure and Improve Adherence to Ocular Medications
Glaucoma is the second leading cause of visual impairment worldwide. Eye drop medications reduce vision loss from glaucoma by at least 60%, but eye drops must be taken every day to be effective.
- Trial name
- NCT03506568
- Testing
- Devers Drop Device (D3) app
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Universal Adherence LLC
Glaucoma
Efficacy of Changing to DuoTrav® (Travoprost 0.004%/Timolol 0.5% BAK-Free Fixed Combination) From Prior Therapy
The purpose of this study is to assess efficacy and tolerability of changing to DuoTrav® (Travoprost 0.004%/Timolol 0.5% BAK-free) from prior Xalacom® or Ganfort® fixed combination pharmacotherapy in patients with open-angle…
- Trial name
- NCT01514721
- Testing
- Travoprost/Timolol Maleate BAK-Free Fixed Combination
- Where
- Brazil
- Volunteers
- 37 people
- Sponsor
- Alcon Research
Primary Open Angle Glaucoma
CRISPR/Cas9 Instantaneous Gene Editing Therapy to Intraocular Hypertensive POAG With MYOC Mutation
This study is intented to evaluate the safety, tolerability and preliminary efficacy of CRISPR/Cas9 Instantaneous Gene Editing Therapy (BD113 virus-like particle, also BD113vLVP) in patients with primary open-angle glaucoma…
- Trial name
- NCT06465537
- Testing
- BD113vVLP
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Shanghai BDgene Co., Ltd.
Primary Angle Closure Glaucoma, Primary Angle Closure
Hydrus Microstent and Lens Extraction for the Treatment of Primary Angle-Closure Glaucoma
This study is a prospective evaluation of the Hydrus Microstent for the treatment of Primary Angle Closure (PAC) and Primary Angle Closure Glaucoma (PACG) with adjunctive cataract.
- Trial name
- NCT04622605
- Testing
- Trabecular bypass and Schlemm's canal stent
- Where
- Philippines
- Volunteers
- 31 people
- Sponsor
- Asian Eye Institute
Primary Open Angle Glaucoma, Ocular Hypertension
Non-inferiority of PRO-067 Ophthalmic Solution vs GAAP Ofteno® in Glaucoma or Ocular Hypertension
Aim: To demonstrate the non-inferiority of the PRO-067 ophthalmic solution manufactured by Laboratorios Sophia S.A. de C.V. versus GAAP Ofteno® ophthalmic solution like hypotensive therapy in subjects with primary open angle…
- Trial name
- COMPLIANCE (NCT02801617)
- Testing
- PRO-067, GAAP Ofteno®
- Where
- Mexico
- Volunteers
- 116 people
- Sponsor
- Laboratorios Sophia S.A de C.V.
Glaucoma, Open-Angle, Ocular Hypertension
Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension
This study will evaluate the safety and efficacy of Triple Combination Therapy compared with Fixed Combination brimonidine tartrate/timolol ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension.
- Trial name
- NCT01217606
- Testing
- bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy), Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution
- Where
- Brazil
- Volunteers
- 185 people
- Sponsor
- Allergan
Open-angle Glaucoma, Ocular Hypertension
A Study of DE-111A on the Treatment of Open Angle Glaucoma or Ocular Hypertension
The objective of this study is to investigate whether the IOP (intraocular pressure) -lowering effect of DE-111A (preservative-free fixed dose combination of 0.0015% tafluprost and 0.5% timolol eye drops, administered one drop a…
- Trial name
- NCT03822559
- Testing
- A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost and 5.0mg of timolol in 1mL, A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost in 1mL
- Where
- 2 sites in China
- Volunteers
- 219 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.